Citations

Clear

154 citation(s) found for "Levin, G".

An investigation of vascular anomalies centers' transition of care practices
Kinariwalla, Neha , Scollan, Margaret E. , Levin, Laura E. , Faith, Esteban Fernández , Lee, Margaret T., Powell, Julie , Tollefson, Megha M. , Lauren, Christine T. , Morel, Kimberly D. , Garzón, Maria C. , Fernandez Faith, Esteban , Baselga, Eulalia , Baselga, Eulàlia

Mayo Clinic

Pediatric Dermatology | July 12, 2023 | Volume: 40 | Issue: 5 | Pages: 866-868

10.1111/pde.15391 | PMID 37437894 Get It

AbstractThis study aims to examine transition of care (TOC) practices of multidisciplinary vascular anomalies centers (VACs). Thirty‐seven of 71 VAC leaders to whom the survey was sent completed the questionnaire. TOC and transfer practices varied with only 16% of VACs having TOC programs. The most frequently cited barriers to developing a TOC program were lack of resources and difficulty finding expert adult providers.
Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma
Levin, Solomon , Tomasini, Michael D. , Knox, James , Shirani, Mahsa , Shebl, Bassem , Requena, David , Clark, Jackson, Heissel, Søren , Alwaseem, Hanan , Surjan, Rodrigo C. , Lahasky, Ron, Molina, Henrik , Lyons, Barbara A. , Migler, Rachael D. , Levin, Solomon N , Surjan, Rodrigo , Torbenson, Michael S , Lyons, Barbara , Migler, Rachael D , Coffino, Philip , Simon, Sanford M , Requena, David , Torbenson, Michael , Simon, Sanford M.

Mayo Clinic

Science Advances | June 21, 2023 | Volume: 9 | Issue: 25 | Pages: No page available

10.1126/sciadv.adg7038 | PMID 37343102 Get It

Fibrolamellar hepatocellular carcinoma (FLC) is a usually lethal primary liver cancer driven by a somatic dysregulation of protein kinase A. We show that the proteome of FLC tumors is distinct from that of adjacent nontransformed tissue. These changes can account for some of the cell biological and pathological alterations in FLC cells, including their drug sensitivity and glycolysis. Hyperammonemic encephalopathy is a recurrent problem in these patients, and established treatments based on the assumption of liver failure are unsuccessful. We show that many of the enzymes that produce ammonia are increased and those that consume ammonia are decreased. We also demonstrate that the metabolites of these enzymes change as expected. Thus, hyperammonemic encephalopathy in FLC may require alternative therapeutics.
Seizure Forecasting and Detection with Wearable Devices and Subcutaneous EEG – Outcomes from the My Seizure Gauge Trial (PL4.001)
Gregg, Nicholas M. , Gregg, Nicholas M , Brinkmann, Benjamin H. , Nurse, Ewan S. , Viana, Pedro F. , Nasseri, Mona , Kuhlmann, Levin , Karoly, Philippa J. , Attia, Tal Pal , Joseph, Boney , Dümpelmann, Matthias , Cook, Mark , Worrell, Gregory A. , Schulze‐Bonhage, Andreas , Richardson, Mark, Freestone, Dean R.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203901 Get It

Carbonic Anhydrase Inhibitor Modulation of Intraocular Pressure Is Independent of Soluble Adenylyl Cyclase
Wiggins, Shakarr V., Schreiner, Ryan , Ferreira, Jacob , Marmorstein, Alan D. , Levin, Lonny R. , Buck, Jochen , Marmorstein, Alan D

Mayo Clinic

Journal of Ocular Pharmacology and Therapeutics | April 25, 2023 | Volume: 39 | Issue: 5 | Pages: 317-323

10.1089/jop.2022.0180 | PMID 37097314 Get It

A novel prostate cancer subtyping classifier based on luminal and basal phenotypes
Weiner, Adam B. , Hakansson, Alex, Zhao, Xin , Proudfoot, James A. , Ho, Julian, Zhang, JJ H., Li, Eric V. , Karnes, R. Jeffrey , Kishan, Amar U. , Reiter, Robert E. , Hamid, Anis , Ross, Ashely E., Spratt, Daniel E. , Chua, Melvin L.K. , Sweeney, Christopher J. , Schaeffer, Edward M. , Li, Eric V , Hamid, Anis A , Spratt, Daniel E , Sweeney, Christopher , Chua, Melvin L K , Liu, Yang , Den, Robert B. , Ross, Ashely E., Tran, Phuoc T , Davicioni, Elai , Attard, Gerhardt , Lotan, Tamara Levin , Zhang, JJ H.

Mayo Clinic

Cancer | April 15, 2023 | Volume: 129 | Issue: 14 | Pages: 2169-2178

10.1002/cncr.34790 | PMID 37060201 Get It

AbstractBackgroundProstate cancer (PCa) is a clinically heterogeneous disease. The creation of an expression‐based subtyping model based on prostate‐specific biological processes was sought.MethodsUnsupervised machine learning of gene expression profiles from prospectively collected primary prostate tumors (training, n = 32,000; evaluation, n = 68,547) was used to create a prostate subtyping classifier (PSC) based on basal versus luminal cell expression patterns and other gene signatures relevant to PCa biology. Subtype molecular pathways and clinical characteristics were explored in five other clinical cohorts.ResultsClustering derived four subtypes: luminal differentiated (LD), luminal proliferating (LP), basal immune (BI), and basal neuroendocrine (BN). LP and LD tumors both had higher androgen receptor activity. LP tumors also had a higher expression of cell proliferation genes, MYC activity, and characteristics of homologous recombination deficiency. BI tumors possessed significant interferon γactivity and immune infiltration on immunohistochemistry. BN tumors were characterized by lower androgen receptor activity expression, lower immune infiltration, and enrichment with neuroendocrine expression patterns. Patients with LD tumors had less aggressive tumor characteristics and the longest time to metastasis after surgery. Only patients with BI tumors derived benefit from radiotherapy after surgery in terms of time to metastasis (hazard ratio [HR], 0.09; 95% CI, 0.01–0.71; n = 855). In a phase 3 trial that randomized patients with metastatic PCa to androgen deprivation with or without docetaxel (n = 108), only patients with LP tumors derived survival benefit from docetaxel (HR, 0.21; 95% CI, 0.09–0.51).ConclusionsWith the use of expression profiles from over 100,000 tumors, a PSC was developed that identified four subtypes with distinct biological and clinical features.Plain language summary Prostate cancer can behave in an indolent or aggressive manner and vary in how it responds to certain treatments. To differentiate prostate cancer on the basis of biological features, we developed a novel RNA signature by using data from over 100,000 prostate tumors—the largest data set of its kind. This signature can inform patients and physicians on tumor aggressiveness and susceptibilities to treatments to help personalize cancer management.
Microfibrillar-associated Protein 4 as Potential Marker of Acute Relapse in Inflammatory Demyelinating Diseases of the Central Nervous System: Pathological and Clinical Aspects
Olesen, Mads Nikolaj , Wirenfeldt, Martin , Ruprecht, Klemens , Marignier, Romain , Lillevang, Søren Thue , Pittock, Sean J. , Kim, Ho Jin , Pittock, S J , Samadzadeh, Sara , Möller, Sören , Misu, Tatsuro , Soelberg, Kerstin , Frederiksen, Jette Lautrup , Heegaard, Steffen , Mariotto, Sara , Fujihara, Kazuo , Andersen, Thomas Levin , Flanagan, Eoin P. , Bennett, Jeffrey L. , Paul, Friedemann , Sørensen, Grith Lykke , Weinshenker, Brian G. , Lassmann, Hans , Asgari, Nasrin

Mayo Clinic

No container title available | April 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2787239/v1 Get It

Abstract Background and Objectives: Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein not previously described in the central nervous system (CNS). We aimed to determine MFAP4 CNS expression and measure cerebrospinal fluid (CSF) and serum levels. Methods: Tissue was sampled at autopsy from patients with acute multiple sclerosis (MS) (n=3), progressive MS (n=3), neuromyelitis optica spectrum disorder (NMOSD) (n=2), controls (n=9), including 6 healthy controls (HC). MFAP4 levels were measured in 152 patients (49 MS, 62 NMOSD, 22 myelin oligodendrocyte glycoprotein associated disease (MOGAD), and 19 isolated optic neuritis (ION). Results: MFAP4 localized to the meninges and the vascular/perivascular spaces, particularly intense in the optic nerve. At sites of active inflammation, MFAP4 reactivity was reduced in NMOSD and acute MS and to a lesser degree in progressive MS. CSF MFAP4 levels were reduced in patients during acute attacks compared to HC. There was a positive correlation between number of relapses and CSF MFAP4 levels (rho=0.33, p=0.004). CSF MFAP4 levels were lower in 53 samples obtained at presenting attack (mean U/mL: 14.3, MOGAD 9.7 and ION 14.6 relative to HC 17.9. (p=0.013, p=0.000 and p=0.019 respectively). All patients with acute ON relapse (n=68) had reduced CSF MFAP4 relative to HC (mean U/mL: 14.5 vs. 17.9, p=0.006). CSF MFAP4 levels correlated negatively with relapse severity (rho=-0.41, p=0.017). Discussion.: MFAP4 immunoreactivity was observed in CNS and reduced at sites of active inflammation. CSF levels of MFAP4 were reduced following acute relapse and may serve as a marker of disease activity and attack severity.
Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.
Hakansson, Alexander K., Proudfoot, James Alexander, Karnes, R. Jeffrey , Kishan, Amar U. , Reiter, Robert E. , Hamid, Anis , Ross, Ashley E. , Weiner, Adam B. , Liu, Yang , Hakansson, Alexander K., Zhao, Xin, Zhang, JJ H. , Den, Robert B. , Tran, Phuoc T , Chua, Melvin L.K. , Spratt, Daniel E. , Attard, Gerhardt , Lotan, Tamara Levin , Sweeney, Christopher J. , Davicioni, Elai , Schaeffer, Edward M.

Mayo Clinic

Journal of Clinical Oncology | March 14, 2023 | Volume: 41 | Issue: 6_suppl | Pages: 241-241

10.1200/jco.2023.41.6_suppl.241 Get It

241 Background: We previously reported on the use of gene expression profiling to characterize four primary subtypes in an analysis of over 100,000 prostate cancer primary tumors. Here we examine these subtypes and response to radiation (RT) after prostatectomy or chemotherapy in addition to androgen deprivation therapy (ADT) in hormone-sensitive metastatic prostate cancer (mHSPC). Methods: We examined a 215-gene prostate subtyping classifier (PSC) which groups luminal and basal gene expression profiles into one of four subtypes; luminal differentiated (LD), luminal proliferating (LP), basal immune (BI) and basal neuroendocrine-like (BN). The log-rank method was used to compare (i) metastasis-free survival between patients who did and did not receive salvage RT in the META855 cohort of localized disease patients treated with radical prostatectomy (n=855) and the (ii) overall survival of patients on the Phase III mHSPC EA3805 CHAARTED trial of ADT or ADT + docetaxel chemotherapy (n=160). Results: After radical prostatectomy, patients with BI tumors derived benefit from RT in terms of metastasis-free survival ( P=9.23e-4) while those with other subtype tumors did not (Each Log-rank P≥0.5). Patients with metastatic disease and LP tumors derived benefit from docetaxel (Log-rank P=0.002) while those with other subtypes tumors did not (Log-rank P=0.2). Conclusions: Basal-luminal subtyping segments tumors by relevant biological processes with potential implications for identifying patients who benefit from salvage radiation post prostatectomy and addition of docetaxel to ADT in mHSPC.
Abstract PR012: Pre-malignant plasma cells exhibit a senescence-like phenotype and accumulation of transposable elements
Guilatco, Angelo Jose, Hachfeld, Christine, Ruan, Ming, Royzenblat, Sonya , Xu, Ming, Kourelis, Taxiarchis , Kirkland, James L. , Weivoda, Megan , Borges, Gabriel Álvares , Edwards, Claire M. , Diaz‐delCastillo, Marta , Andersen, Thomas Levin , Tchkonia, Tamar , Drake, Matthew T.

Mayo Clinic

Cancer Research | January 18, 2023 | Volume: 83 | Issue: 2_Supplement_1 | Pages: PR012-PR012

10.1158/1538-7445.agca22-pr012 Get It

Abstract Multiple myeloma (MM) is a clonal plasma cell (PC) cancer that is preceded by the benign conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). While MGUS/SMM PCs are not proliferative, many of the oncogenes and chromosomal abnormalities in MM PCs are also present in MGUS/SMM. Since oncogenic stress is known to induce cellular senescence, we hypothesized that MGUS/SMM PCs may be in a senescent-like state. Our analysis of a published human dataset (GSE5900) revealed that compared to healthy PCs, MGUS/SMM PCs had significantly increased expression of senescence markers CDKN1A and GADD45A (FDR<0.05). Gene Set Enrichment Analysis (GSEA) showed significant enrichment in MGUS/SMM PCs of our customized senescence phenotyping gene sets (q<0.25). We next evaluated the KaLwRij MGUS mouse model. 10-mo-old female KaLwRij mice were treated with placebo or senolytics (dasatinib+quercetin, D+Q). D+Q treatment significantly reduced PCs compared to placebo, while restoring B cell number and functional gene expression. PCs isolated from D+Q-treated KaLwRij mice exhibited significant reductions in Myc and Il1b expression (p<0.05) versus placebo and a trend towards reduced Trp53 expression (p=0.13), supporting that senescent PCs are targeted by D+Q. Single-cell RNA-seq and single sample (ss)GSEA of 24-mo-old KaLwRij PCs revealed a PC subset enriched for the ‘Plasma Cell Senescence’ gene set, which included genes from our customized gene sets that were differentially expressed in the human PCs dataset GSE5900. Notably, PCs in this subset showed enrichment for ‘Inflammatory SASP’ (median: 15.26%) and ‘Interferon (IFN) SASP’ (39.36%) gene sets. The IFN-SASP is characteristic of late senescence, driven by the accumulation of transposable elements. In the GSE5900 dataset, we found significant enrichment of ‘IFN-SASP’ in SMM (q<0.25) but not MGUS PCs. Further, whole transcriptome RNA-sequencing showed that SMM PCs had increased expression of LINE1 retrotransposon L1HS in relation to normal PCs (FDR<0.1), but not MGUS (FDR=0.83) or MM (FDR=0.5) PCs. Immunostaining confirmed increased cytosolic DNA:RNA hybrids in SMM (median frequency of cells exceeding the intensity threshold = 33%) versus MGUS (16.4%), MM (4.4%), and healthy PCs (1.5%), which is consistent with cytosolic DNA-mediated activation of the IFN SASP in SMM PCs. When these same patients were redistributed according to disease progression, L1HS was higher in patients with progressing SMM and newly diagnosed MM (NDMM) (FDR<0.1) versus patients with stable MGUS (FDR=0.56) or advanced MM (FDR=0.38). Increased DNA:RNA staining was observed in progressing SMM PCs (median frequency = 41%), but the results for NDMM patients (4.4%) and advanced MM (3%) were comparable to healthy or stable patients (3.5%). These data demonstrate that MGUS and SMM PCs exhibit senescence features, suggest mechanisms that may contribute to MM tumorigenesis, and show that pharmacological ablation of senescent cells may prevent progression from MGUS/SMM to MM. Citation Format: Gabriel Alvares Borges, Angelo Jose Guilatco, Christine M. Hachfeld, Ming Ruan, Sonya Royzenblat, Ming Xu, Claire M. Edwards, Marta Diaz-delCastillo, Thomas L. Andersen, Taxiarchis Kourelis, Tamar Tchkonia, James L. Kirkland, Matthew T. Drake, Megan Weivoda. Pre-malignant plasma cells exhibit a senescence-like phenotype and accumulation of transposable elements [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr PR012.
Abstract B020: Pre-malignant plasma cells exhibit a senescence-like phenotype and accumulation of transposable elements
Guilatco, Angelo Jose, Hachfeld, Christine, Ruan, Ming, Royzenblat, Sonya , Xu, Ming, Kourelis, Taxiarchis , Kirkland, James L. , Weivoda, Megan , Borges, Gabriel Álvares , Edwards, Claire M. , Diaz‐delCastillo, Marta , Andersen, Thomas Levin , Tchkonia, Tamar , Drake, Matthew T.

Mayo Clinic

Cancer Research | January 18, 2023 | Volume: 83 | Issue: 2_Supplement_1 | Pages: B020-B020

10.1158/1538-7445.agca22-b020 Get It

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is available in the Short Talks from Proffered Abstracts section (PR012) of the Conference Proceedings. Citation Format: Gabriel Alvares Borges, Angelo Jose Guilatco, Christine M. Hachfeld, Ming Ruan, Sonya Royzenblat, Ming Xu, Claire M. Edwards, Marta Diaz-delCastillo, Thomas L. Andersen, Taxiarchis Kourelis, Tamar Tchkonia, James L. Kirkland, Matthew T. Drake, Megan Weivoda. Pre-malignant plasma cells exhibit a senescence-like phenotype and accumulation of transposable elements [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr B020.
Neurodegenerative Pathways in Alzheimer's Disease Subtypes
Wheatley, Sophia , Muehlboeck, J‐Sebastian, Levin, Fedor , Mohanty, Rosaleena , Ferreira, Daniel , Grothe, Michel J. , Westman, Eric

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.067749 Get It

AbstractBackgroundBiological heterogeneity in Alzheimer’s disease (AD) has been observed and described as subtypes in measures of neurodegeneration (e.g., hypometabolism and atrophy). However, the relationship between these AD subtypes have not been studied. Thus, we aimed to compare and identify pathways associated with hypometabolism‐based and atrophy‐based subtypes.MethodCross‐sectional FDG‐PET and MRI scans from 173 amyloid‐positive AD individuals and 120 amyloid‐negative cognitively normal control individuals from the ADNI were included. Subtypes were identified in each neuroimaging modality by random forest hierarchical clustering using FDG‐PET uptake (measuring hypometabolism) and MRI volumes (measuring atrophy) in cortical and subcortical regions. We performed cross‐modal comparisons of atrophy patterns in hypometabolism‐based subtypes and hypometabolism patterns in atrophy‐based subtypes. To identify neurodegenerative pathways corresponding to each subtype, we used event‐based modelling to predict sequential progression of abnormality in hypometabolism and atrophy across brain regions (hippocampus, AD signature, frontal, posterior areas).ResultClustering revealed four hypometabolism‐based (two relatively limbic‐predominant: 25.7%, 19.8% and two relatively cortical‐predominant: 25.7%, 28.6%) and three atrophy‐based (diffuse: 18.7%, relatively limbic‐predominant: 28.6%, minimal: 52.6%) subtypes of AD with distinct spatial patterns and demographic and clinical characteristics. Cross‐modally, we found comparable AD‐typical atrophy patterns (involving the hippocampus and temporal regions) across the four hypometabolism‐based subtypes and comparable AD‐typical hypometabolism patterns (involving the retrosplenial cortex) across the three atrophy‐based subtypes. Event‐based modelling showed that each hypometabolism‐based subtype was associated with a unique sequential progression of regional hypometabolism, but not regional atrophy (sequence always initiated with frontal atrophy across all subtypes). Similarly, each atrophy‐based subtype was associated with a unique sequential progression of regional atrophy, but not regional hypometabolism (sequence always initiated with hypometabolism in AD signature areas across all subtypes).ConclusionOur findings suggest that hypometabolism‐based and atrophy‐based AD subtypes are not interchangeable. We identified unique metabolic and atrophy pathways specific to each subtype, which supports the notion that neurodegeneration manifests and progresses differentially across subtypes of AD. Despite being measures of neurodegeneration, hypometabolism and atrophy may not share the same extent of heterogeneity, bearing a complex multimodal relationship. Disentangling such relationships and combining complementary biomarkers to investigate heterogeneity could aid personalized treatment of AD.